{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:36:23Z","timestamp":1790620583117,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"am","delay-in-days":341,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-18-1-0576"],"award-info":[{"award-number":["W81XWH-18-1-0576"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-19-1-0390"],"award-info":[{"award-number":["W81XWH-19-1-0390"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32CA240172-05"],"award-info":[{"award-number":["5T32CA240172-05"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA218356"],"award-info":[{"award-number":["R01CA218356"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.drup.2025.101207","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T11:25:52Z","timestamp":1738063552000},"page":"101207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["B7-H3-liquid biopsy for the characterization and monitoring of the dynamic biology of prostate cancer"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9550-4866","authenticated-orcid":false,"given":"Yong","family":"Ju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine J.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Tzu","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilit","family":"Gevorkian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai Han","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Salumbides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6656-475X","authenticated-orcid":false,"given":"Aaron","family":"Phung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8931-8298","authenticated-orcid":false,"given":"Hyoyong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Ren","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junseok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungyong","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4036-6969","authenticated-orcid":false,"given":"Jie-Fu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsian-Rong","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazhen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8649-1346","authenticated-orcid":false,"given":"Edwin M.","family":"Posadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.drup.2025.101207_bib1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13045-022-01364-7","article-title":"Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy","volume":"15","author":"Zhao","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.drup.2025.101207_bib2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/gb-2005-6-6-223","article-title":"The B7 family of immune-regulatory ligands","volume":"6","author":"Collins","year":"2005","journal-title":"Genome Biol."},{"issue":"1","key":"10.1016\/j.drup.2025.101207_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12943-023-01751-9","article-title":"New frontiers in immune checkpoint B7-H3 (CD276) research and drug development","volume":"22","author":"Getu","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2025.101207_bib4","article-title":"B7-H3\/CD276: an emerging cancer immunotherapy","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.drup.2025.101207_bib5","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1038\/s41417-023-00644-9","article-title":"Influence of ADT on B7-H3 expression during CRPC progression from hormone-naive prostate cancer","volume":"30","author":"Kang","year":"2023","journal-title":"Cancer Gene Ther."},{"issue":"12","key":"10.1016\/j.drup.2025.101207_bib6","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/pros.24180","article-title":"Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer","volume":"81","author":"Nunes-Xavier","year":"2021","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.drup.2025.101207_bib7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/pcan.2016.49","article-title":"Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis","volume":"20","author":"Benzon","year":"2017","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"16","key":"10.1016\/j.drup.2025.101207_bib8","doi-asserted-by":"crossref","first-page":"7893","DOI":"10.1158\/0008-5472.CAN-07-1068","article-title":"B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy","volume":"67","author":"Roth","year":"2007","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.drup.2025.101207_bib9","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41391-021-00331-6","article-title":"Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer","volume":"24","author":"Amori","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"3","key":"10.1016\/j.drup.2025.101207_bib10","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.eururo.2022.09.004","article-title":"B7-H3 as a therapeutic target in advanced prostate cancer","volume":"83","author":"Guo","year":"2023","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.drup.2025.101207_bib11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40364-021-00267-y","article-title":"Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer","volume":"9","author":"Zhang","year":"2021","journal-title":"Biomark. Res"},{"issue":"2","key":"10.1016\/j.drup.2025.101207_bib12","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/pros.22742","article-title":"Distribution of metastatic sites in patients with prostate cancer: a population-based analysis","volume":"74","author":"Gandaglia","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.drup.2025.101207_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2022.101746","article-title":"Prostate cancer extracellular vesicle digital scoring assay - a rapid noninvasive approach for quantification of disease-relevant mRNAs","volume":"48","author":"Wang","year":"2023","journal-title":"Nano Today"},{"issue":"1","key":"10.1016\/j.drup.2025.101207_bib14","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1038\/s41467-020-18311-0","article-title":"Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring","volume":"11","author":"Sun","year":"2020","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.drup.2025.101207_bib15","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hep.32692","article-title":"HCC EV ECG score: an extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma","volume":"77","author":"Sun","year":"2023","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.drup.2025.101207_bib16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrm.2017.125","article-title":"Shedding light on the cell biology of extracellular vesicles","volume":"19","author":"van Niel","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"8","key":"10.1016\/j.drup.2025.101207_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cells7080093","article-title":"The role of extracellular vesicles in cancer: cargo, function, and therapeutic implications","volume":"7","author":"Jabalee","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.drup.2025.101207_bib18","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1186\/1471-2407-12-421","article-title":"Hypoxic enhancement of exosome release by breast cancer cells","volume":"12","author":"King","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drup.2025.101207_bib19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3389\/fgene.2013.00142","article-title":"The origin, function, and diagnostic potential of RNA within extracellular vesicles present in human biological fluids","volume":"4","author":"Taylor","year":"2013","journal-title":"Front. Genet"},{"issue":"6","key":"10.1016\/j.drup.2025.101207_bib20","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.jhep.2020.07.014","article-title":"Extracellular vesicles as biomarkers in liver diseases: a clinician's point of view","volume":"73","author":"Thietart","year":"2020","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.drup.2025.101207_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13123076","article-title":"The role of extracellular vesicles in disease progression and detection of hepatocellular carcinoma","volume":"13","author":"Lee","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"49","key":"10.1016\/j.drup.2025.101207_bib22","article-title":"Coupling nanostructured microchips with covalent chemistry enables purification of sarcoma-derived extracellular vesicles for downstream functional studies","volume":"30","author":"Dong","year":"2020","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.drup.2025.101207_bib23","article-title":"Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles","volume":"3","author":"Lotvall","year":"2014","journal-title":"J. Extra Vesicles"},{"issue":"1","key":"10.1016\/j.drup.2025.101207_bib24","article-title":"Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines","volume":"7","author":"Thery","year":"2018","journal-title":"J. Extra Vesicles"},{"issue":"7757","key":"10.1016\/j.drup.2025.101207_bib25","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","article-title":"Next-generation characterization of the cancer cell line encyclopedia","volume":"569","author":"Ghandi","year":"2019","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.drup.2025.101207_bib26","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.7150\/ijbs.41105","article-title":"B7-H3, a checkpoint molecule, as a target for cancer immunotherapy","volume":"16","author":"Yang","year":"2020","journal-title":"Int J. Biol. Sci."},{"issue":"4","key":"10.1016\/j.drup.2025.101207_bib27","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/s41591-023-02284-w","article-title":"Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial","volume":"29","author":"Shenderov","year":"2023","journal-title":"Nat. Med"},{"issue":"Pt B","key":"10.1016\/j.drup.2025.101207_bib28","article-title":"The role of B7-H3 in tumors and its potential in clinical application","volume":"101","author":"Feng","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.drup.2025.101207_bib29","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.molimm.2021.09.002","article-title":"Co-immunizing with HMGB1 enhances anti-tumor immunity of B7H3 vaccine in renal carcinoma","volume":"139","author":"Sun","year":"2021","journal-title":"Mol. Immunol."},{"issue":"4","key":"10.1016\/j.drup.2025.101207_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004424","article-title":"Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I\/II trial","volume":"10","author":"Aggarwal","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"15_","key":"10.1016\/j.drup.2025.101207_bib31","article-title":"A phase 1, open-label, dose escalation study of enoblituzumab (MGA271) in pediatric patients with B7-H3-expressing relapsed or refractory solid tumors","volume":"35","author":"Desantes","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"16_","key":"10.1016\/j.drup.2025.101207_bib32","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1200\/JCO.2023.41.16_suppl.3017","article-title":"ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3\u2013targeting antibody-drug conjugate, in patients with advanced solid tumor","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2025.101207_bib33","doi-asserted-by":"crossref","first-page":"S528","DOI":"10.1016\/j.annonc.2021.08.044","article-title":"380TiP A phase I\/II dose-escalation and expansion cohort study of intracerebroventricular radioimmunotherapy using 177Lu-DTPA-omburtamab in pediatric and adolescent patients with recurrent or refractory medulloblastoma","volume":"32","author":"Khatua","year":"2021","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.drup.2025.101207_bib34","article-title":"397\u2005A phase I\/II trial of intracerebroventricular 177Lu DTPA omburtamab radioimmunotherapy for leptomeningeal metastasis from solid tumors","volume":"9","author":"Pentsova","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.drup.2025.101207_bib35","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ymthe.2023.02.010","article-title":"An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers","volume":"31","author":"Zekri","year":"2023","journal-title":"Mol. Ther."},{"issue":"15_","key":"10.1016\/j.drup.2025.101207_bib36","article-title":"A phase 1, open label, dose escalation study of MGD009, a humanized B7-H3 x CD3 DART protein, in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory B7-H3-expressing tumors","volume":"36","author":"Shankar","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.drup.2025.101207_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113503","article-title":"Engineering CD276\/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability","volume":"42","author":"Feng","year":"2023","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.drup.2025.101207_bib38","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12935-023-02991-x","article-title":"ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors","volume":"23","author":"Shin","year":"2023","journal-title":"Cancer Cell Int"},{"issue":"15_","key":"10.1016\/j.drup.2025.101207_bib39","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1200\/JCO.2021.39.15_suppl.2631","article-title":"Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors","volume":"39","author":"Jang","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.drup.2025.101207_bib40","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/j.jtho.2023.09.042","article-title":"OA05. 05 ifinatamab deruxtecan (I-DXd; DS-7300) in patients with refractory SCLC: A subgroup analysis of a phase 1\/2 study","volume":"18","author":"Johnson","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"7_ement","key":"10.1016\/j.drup.2025.101207_bib41","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1158\/1538-7445.AM2023-2967","article-title":"Abstract 2967: Preclinical development of a B7-H3-targeting ADC with a novel DNA topoisomerase I inhibitor for solid tumors","volume":"83","author":"Li","year":"2023","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.drup.2025.101207_bib42","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41420-023-01453-7","article-title":"B7-H3 specific CAR-T cells exhibit potent activity against prostate cancer","volume":"9","author":"Li","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.drup.2025.101207_bib43","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3389\/fphar.2020.01089","article-title":"Targeting B7-H3 immune checkpoint with chimeric antigen receptor-engineered natural killer cells exhibits potent cytotoxicity against non-small cell lung cancer","volume":"11","author":"Yang","year":"2020","journal-title":"Front Pharm."},{"issue":"6_","key":"10.1016\/j.drup.2025.101207_bib44","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1200\/JCO.2022.40.6_suppl.087","article-title":"DS-7300 (B7-H3 DXd-ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): a subgroup analysis of a phase 1\/2 multicenter study","volume":"40","author":"Patel","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.drup.2025.101207_bib45","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.7150\/thno.25575","article-title":"Molecular imaging of T cell co-regulator factor B7-H3 with (89)Zr-DS-5573a","volume":"8","author":"Burvenich","year":"2018","journal-title":"Theranostics"},{"issue":"9","key":"10.1016\/j.drup.2025.101207_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14091780","article-title":"Evaluation of an affibody-based binder for imaging of immune check-point molecule B7-H3","volume":"14","author":"Oroujeni","year":"2022","journal-title":"Pharmaceutics"},{"issue":"16_ement","key":"10.1016\/j.drup.2025.101207_bib47","article-title":"Analytical validation of Illumina's TruSight Oncology 500 ctDNA assay","volume":"80","author":"Verhein","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2025.101207_bib48","doi-asserted-by":"crossref","first-page":"69","DOI":"10.18632\/oncoscience.592","article-title":"Evolving insights in blood-based liquid biopsies for prostate cancer interrogation","volume":"10","author":"Bonfil","year":"2023","journal-title":"Oncoscience"},{"issue":"8","key":"10.1016\/j.drup.2025.101207_bib49","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.cell.2023.03.010","article-title":"The role of extracellular vesicles in cancer","volume":"186","author":"Kalluri","year":"2023","journal-title":"Cell"}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S136876462500007X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S136876462500007X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T12:50:22Z","timestamp":1774270222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S136876462500007X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":49,"alternative-id":["S136876462500007X"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2025.101207","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"B7-H3-liquid biopsy for the characterization and monitoring of the dynamic biology of prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2025.101207","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101207"}}